EOFlow ordered to pay rival $452m over insulin patch trade secrets

Jury finds medical device company misappropriated secrets covering Insulet’s Omnipod l Insulet “extremely pleased” with verdict l Federal circuit overturned ban on EOFlow’s product in June.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Federal Circuit overturns ban on EOFlow’s insulin pump patches

18 June 2024 Judge says lower court abused discretion when issuing injunction | Negative impact of potential Medtronic deal on Insulet was “mere conjecture”.

Big Pharma

Medtronic’s $738m deal with insulin maker at risk

12 October 2023 Insulet has been awarded a preliminary injunction against EOFlow on its insulin patch pump products | Dispute and injunction come ahead of Medtronic’s planned $738m acquisition of EOFlow.

More features

IP agencies vital to pharma and biotech grind to a halt

USPTO trims workforce amid govt shutdown crisis

How impactful is the new USPTO director’s S101 decision?

Global vaccine patents rise, as data reveals shift in Big Pharma strategy

Philips wins unprecedented trade secret sanctions against Chinese defendants

Womble Bond Dickinson partners jump to rival firm

EPO ruling clarifies appeal rights, blocking third-party intervention

Biotech sues AstraZeneca and Cellectis over mRNA patents

EOFlow ordered to pay rival $452m over insulin patch trade secrets

More on this story

Editor's picks

Editor's picks

More features